Trexquant Investment’s Recursion Pharmaceuticals RXRX Stock Holding History

Trexquant Investment’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-228,754	Closed	-$1.12M	–	1881
2025 Q3	$1.12M	Buy	+228,754	New	+$1.2M	0.01%	1114
2023 Q2	–	Sell	-200,366	Closed	-$1.34M	–	1754
2023 Q1	$1.34M	Buy	200,366 +71,693	+56%	+$569K	0.04%	610
2022 Q4	$992K	Buy	128,673 +116,873	+990%	+$1.15M	0.03%	646
2022 Q3	$126K	Sell	11,800 -42,457	-78%	-$430K	﹤0.01%	1264
2022 Q2	$442K	Buy	+54,257	New	+$363K	0.02%	899
2022 Q1	–	Sell	-12,050	Closed	-$206K	–	1671
2021 Q4	$206K	Buy	+12,050	New	+$227K	0.01%	1133

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Trexquant Investment's RXRX Position: Q4 2025 in Review

Trexquant Investment sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 228,754 shares — an estimated $1.12M sold.

Trexquant Investment first reported a position in RXRX in Q4 2021 and held it in 6 quarters. The position peaked at $1.34M in Q1 2023. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Trexquant Investment reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Trexquant Investment sold 228,754 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.12M.
Trexquant Investment first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Trexquant Investment's Recursion Pharmaceuticals position peaked at $1.34M in Q1 2023.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.